Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

Phase 2 Completed 39 enrolled M.D. Anderson Cancer Center Novartis Pharmaceuticals · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Primary Objective: 1\. To evaluate the pathological complete response rate to neoadjuvant hormonal ablation, Imatinib and Docetaxel (HID) in high-risk localized prostate cancer. Secondary Objectives: 1. To describe the time to prostate specific antigen (PSA)-progression after neoadjuvant HID and radical prostatectomy in high-risk localized prostate cancer. 2. To correlate pathological response with modulation of the Platelet-Derived Growth Factor Receptor (PDGFR) pathway.

Timeline

Start: 2003-06
Primary completion: 2010-02
Completion: 2010-02

Publications

Results Mathew P, Pisters LL, Wood CG, Papadopoulos JN, Williams DL, Thall PF, Wen S, Horne E, Oborn CJ, Langley R, Fidler IJ, Pettaway CA. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol. 2009 Jan;181(1):81-7; discussion 87. doi: 10.1016/j.juro.2008.09.006. Epub 2008 Nov 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Docetaxel	Small molecule	30 mg/m2	Intravenous
Subject	Imatinib	Small molecule	600 mg	Oral
Background	Goserelin	Other / unclassified	—	—
Background	Leuprolide	Other / unclassified	—	Intramuscular

Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications